Drug Type Small molecule-drug conjugates |
Synonyms QHL 1231, QHL1231 |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | IND Approval | China | 28 Aug 2026 | |
| Liver Cancer | IND Approval | China | 28 Aug 2026 | |
| Lung Cancer | IND Approval | China | 28 Aug 2026 | |
| Stomach Cancer | IND Approval | China | 28 Aug 2026 | |
| Advanced Malignant Solid Neoplasm | IND Approval | China | 28 Aug 2026 | |
| Colorectal Cancer | IND Approval | China | 28 Aug 2026 |





